Table of Contents

Assessing the Value of New Drugs

Pharmaceutical Benefits Scheme

Background

Background

Background

Commonwealth Health Expenditure:$27 billion 2000-2001

The PBS in Australia

The PBS in Australia

Patient Co-payment : Safety Net

Pharmaceutical Expenditure

Commonwealth PBS, Public hospital & MBS expenditure: % growth since 90/91

National Medicines Policy

National Medicines Policy

Access to Medicines

Access to Medicines

Drug regulation: from new drug application to the prescription pad

TGA approval

PBAC processes

Assessment of evidence

PBAC processes

Economic evaluation

Economic evaluation

Relevant factors

Relevant factors

Relevant factors

PBAC recommendations

RULE OF RESCUE

Restrictions

Restrictions

Levels of restriction

Initiation and continuing requirements: examples

Registration vs subsidy

Pharmaceutical Benefits Pricing Authority

Pricing and cost containment

Drug Prices

Ratio of prices for Paroxitene

"Me-too" pharmaceuticals

New innovative drugs

Generic pharmaceuticals

The Future

Future

Future

Future

Future

Transparency

COX-2 selective NSAIDs

New agents with limited data

“Leakage”

Trial data vs “in use” data

Future-necessity

Future-necessity

Future-necessity

Future-necessity

Presentation Author

Professor Lloyd Sansom AO, Chair, PBAC, Australia

PMPRB Email

pmprb@pmprb-cepmb.gc.ca

PMPRB Symposium 2002, List of Presentations

http://www.pmprb.com/symposium2002/present-e.html

Author: Professor Lloyd Sansom AO, Chair, PBAC, Australia

Email: pmprb@pmprb-cepmb.gc.ca

Home Page: http://www.pmprb.com/symposium2002/present-e.html